227 related articles for article (PubMed ID: 30561782)
1. The who, when, and why of primary adrenal malignancies: Insights into the epidemiology of a rare clinical entity.
Chandrasekar T; Goldberg H; Klaassen Z; Wallis CJD; Woon DTS; Herrera-Caceres JO; Kulkarni GS; Fleshner NE
Cancer; 2019 Apr; 125(7):1050-1059. PubMed ID: 30561782
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological features of adrenal malignancies: Analysis of hospital-based cancer registry data in Japan.
Chihara I; Nagumo Y; Kandori S; Kojo K; Sano K; Hamada K; Tanuma K; Tsuchiya H; Shiga M; Sakka S; Kimura T; Kawahara T; Hoshi A; Negoro H; Kojima T; Bryan MJ; Okuyama A; Higashi T; Nishiyama H
Int J Urol; 2022 Nov; 29(11):1331-1337. PubMed ID: 35976672
[TBL] [Abstract][Full Text] [Related]
3. Long-term survival outcomes of pediatric adrenal malignancies: An analysis with the upstaged SEER registry during 2000-2019.
Lv Z; Yu Y; Luo Y; Lin S; Xiang X; Mao X; Cheng S
Front Endocrinol (Lausanne); 2022; 13():977105. PubMed ID: 36171902
[TBL] [Abstract][Full Text] [Related]
4. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?
Kebebew E; Reiff E; Duh QY; Clark OH; McMillan A
World J Surg; 2006 May; 30(5):872-8. PubMed ID: 16680602
[TBL] [Abstract][Full Text] [Related]
5. Primary malignant tumors of the adrenal glands.
Almeida MQ; Bezerra-Neto JE; Mendonça BB; Latronico AC; Fragoso MCBV
Clinics (Sao Paulo); 2018 Dec; 73(suppl 1):e756s. PubMed ID: 30540124
[TBL] [Abstract][Full Text] [Related]
6. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Fassnacht M; Assie G; Baudin E; Eisenhofer G; de la Fouchardiere C; Haak HR; de Krijger R; Porpiglia F; Terzolo M; Berruti A;
Ann Oncol; 2020 Nov; 31(11):1476-1490. PubMed ID: 32861807
[No Abstract] [Full Text] [Related]
7. Increased incidence of malignant melanoma and other rare cutaneous cancers in the setting of chronic lymphocytic leukemia.
Brewer JD; Shanafelt TD; Call TG; Cerhan JR; Roenigk RK; Weaver AL; Otley CC
Int J Dermatol; 2015 Aug; 54(8):e287-93. PubMed ID: 25772131
[TBL] [Abstract][Full Text] [Related]
8. Adrenocortical carcinoma: presentation and outcome of a contemporary patient series.
Kostiainen I; Hakaste L; Kejo P; Parviainen H; Laine T; Löyttyniemi E; Pennanen M; Arola J; Haglund C; Heiskanen I; Schalin-Jäntti C
Endocrine; 2019 Jul; 65(1):166-174. PubMed ID: 30980285
[TBL] [Abstract][Full Text] [Related]
9. Non-Hodgkin Lymphoma - Nodal and Extranodal: 20-Year Comparative Mortality, Survival & Biologic Behavior Analysis by Age, Sex, Race, Stage, Cell Morphology/Histology, Cohort Entry Time-Period and Disease Duration: A Systematic Review of 384,651 Total NHL Cases Including 261,144 Nodal and 123,507 Extranodal Cases for Diagnosis Years 1975-2016: (SEER*Stat 8.3.6).
Milano AF
J Insur Med; 2023 Jul; 50(1):1-35. PubMed ID: 37725503
[TBL] [Abstract][Full Text] [Related]
10. Outcome of adrenocortical tumors in children.
Hanna AM; Pham TH; Askegard-Giesmann JR; Grams JM; Iqbal CW; Stavlo P; Moir CR
J Pediatr Surg; 2008 May; 43(5):843-9. PubMed ID: 18485950
[TBL] [Abstract][Full Text] [Related]
11. Malignant adrenal tumors.
Rescorla FJ
Semin Pediatr Surg; 2006 Feb; 15(1):48-56. PubMed ID: 16458846
[TBL] [Abstract][Full Text] [Related]
12. [Malignant tumors of the adrenal: contribution to the repository CCAFU INCa].
Sèbe P; Rigaud J; Avancès C; Brunaud L; Caillard C; Camparo P; Carnaille B; Culine S; Durand X; Mathonnet M; Mirallie E; Soulié M;
Prog Urol; 2010 Nov; 20 Suppl 4():S310-6. PubMed ID: 21129649
[No Abstract] [Full Text] [Related]
13. Disparate Practice Patterns and Survival Outcomes: The Impact of Centralization of Cancer Care for Adrenocortical Carcinoma in the United States.
Stone BV; Tallman JE; Moses KA
J Urol; 2021 Oct; 206(4):866-872. PubMed ID: 34032493
[TBL] [Abstract][Full Text] [Related]
14. Update on the management of unusual neuroendocrine tumors: pheochromocytoma and paraganglioma, medullary thyroid cancer and adrenocortical carcinoma.
Strosberg JR
Semin Oncol; 2013 Feb; 40(1):120-33. PubMed ID: 23391119
[TBL] [Abstract][Full Text] [Related]
15. Predictors of survival in pediatric adrenocortical carcinoma: a Surveillance, Epidemiology, and End Results (SEER) program study.
McAteer JP; Huaco JA; Gow KW
J Pediatr Surg; 2013 May; 48(5):1025-31. PubMed ID: 23701777
[TBL] [Abstract][Full Text] [Related]
16. National Treatment Practice for Adrenocortical Carcinoma: Have They Changed and Have We Made Any Progress?
Tierney JF; Chivukula SV; Poirier J; Pappas SG; Schadde E; Hertl M; Kebebew E; Keutgen X
J Clin Endocrinol Metab; 2019 Dec; 104(12):5948-5956. PubMed ID: 31361313
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology and survival of childhood cancer in Turkey.
Kebudi R; Alkaya DU
Pediatr Blood Cancer; 2021 Feb; 68(2):e28754. PubMed ID: 33034155
[TBL] [Abstract][Full Text] [Related]
18. Clinical management of malignant adrenal tumors.
Kopf D; Goretzki PE; Lehnert H
J Cancer Res Clin Oncol; 2001; 127(3):143-55. PubMed ID: 11260859
[TBL] [Abstract][Full Text] [Related]
19. Conditional survival among patients with adrenal cortical carcinoma determined using a national population-based surveillance, epidemiology, and end results registry.
Xiao WJ; Zhu Y; Dai B; Zhang HL; Shi GH; Shen YJ; Zhu YP; Ye DW
Oncotarget; 2015 Dec; 6(42):44955-62. PubMed ID: 26510907
[TBL] [Abstract][Full Text] [Related]
20. Clinical course and prognostic factors in patients with malignant pheochromocytoma and paraganglioma: A single institution experience.
Choi YM; Sung TY; Kim WG; Lee JJ; Ryu JS; Kim TY; Kim WB; Hong SJ; Song DE; Shong YK
J Surg Oncol; 2015 Dec; 112(8):815-21. PubMed ID: 26464058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
